首页> 外文期刊>Clinical and vaccine immunology: CVI >Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea
【24h】

Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea

机译:针对产肠毒素的大肠埃希菌相关腹泻的亚单位疫苗开发的最新进展

获取原文
获取外文期刊封面目录资料

摘要

Diarrhea continues to be a leading cause of death in children <5 years of age, and enterotoxigenic Escherichia coli (ETEC) is the most common bacterial cause of children's diarrhea. Currently, there are no available vaccines against ETEC-associated diarrhea. Whole-cell vaccine candidates have been under development but require further improvements because they provide inadequate protection and produce unwanted adverse effects. Meanwhile, a newer approach using polypeptide or subunit vaccine candidates focusing on ETEC colonization factor antigens (CFAs) and enterotoxins, the major virulence determinants of ETEC diarrhea, shows substantial promise. A conservative CFA/I adhesin tip antigen and a CFA MEFA (multiepitope fusion antigen) were shown to induce cross-reactive antiadhesin antibodies that protected against adherence by multiple important CFAs. Genetic fusion of toxoids derived from ETEC heat-labile toxin (LT) and heat-stable toxin (STa) induced antibodies neutralizing both enterotoxins. Moreover, CFA-toxoid MEFA polypeptides, generated by fusing CFA MEFA to an STa-LT toxoid fusion, induced antiadhesin antibodies that broadly inhibited adherence of the seven most important ETEC CFAs associated with about 80% of the diarrhea cases caused by ETEC strains with known CFAs. This same antigen preparation also induced antitoxin antibodies that neutralized both toxins that are associated with all cases of ETEC diarrhea. Results from these studies suggest that polypeptide or subunit vaccines have the potential to effectively protect against ETEC diarrhea. In addition, novel adhesins and mucin proteases have been investigated as potential alternatives or, more likely, additional antigens for ETEC subunit vaccine development.
机译:腹泻仍然是5岁以下儿童死亡的主要原因,而产肠毒素的大肠杆菌(ETEC)是儿童腹泻的最常见细菌。当前,没有针对ETEC相关的腹泻的可用疫苗。全细胞疫苗候选者正在开发中,但需要进一步改进,因为它们提供的保护不足并会产生不良的不良反应。同时,一种新的使用多肽或亚基疫苗候选物的新方法显示出了很大的希望,所述多肽或亚基疫苗候选物集中于ETEC腹泻的主要毒力决定因素ETEC定植因子抗原(CFA)和肠毒素。保守的CFA / I粘附素尖端抗原和CFA MEFA(多表位融合抗原)显示出诱导交叉反应的抗粘附素抗体,该抗体可防止多种重要CFA的粘附。源自ETEC热不稳定毒素(LT)和热稳定毒素(STa)的类毒素的遗传融合诱导抗体中和两种肠毒素。此外,通过将CFA MEFA与STa-LT类毒素融合融合而产生的CFA类毒素MEFA多肽诱导的抗粘附素抗体广泛抑制了七个最重要的ETEC CFA的粘附,这与大约80%的由已知ETEC菌株引起的腹泻病例有关CFA。这种相同的抗原制剂还诱导了抗毒素抗体,该抗体中和了与所有ETEC腹泻病例相关的两种毒素。这些研究的结果表明,多肽或亚基疫苗具有有效预防ETEC腹泻的潜力。另外,已经研究了新型粘附素和粘蛋白蛋白酶作为ETEC亚基疫苗开发的潜在替代物,或更可能是其他抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号